0	1	I	i	NN
2	7	kappa	kappa	NN
8	15	B/MAD-3	b/mad-3	NN
16	21	masks	mask	VBZ
22	25	the	the	DT
26	33	nuclear	nuclear	JJ
34	46	localization	localization	NN
47	53	signal	signal	NN
54	56	of	of	IN
57	65	NF-kappa	NF-kappa	NNP
66	67	B	B	NNP
68	71	p65	p65	NN
72	75	and	and	CC
76	84	requires	require	VBZ
85	88	the	the	DT
89	104	transactivation	transactivation	NN
105	111	domain	domain	NN
112	114	to	to	TO
115	122	inhibit	inhibit	VB
123	131	NF-kappa	NF-kappa	NNP
132	133	B	B	NNP
134	137	p65	p65	NN
138	141	DNA	dna	NN
142	149	binding	binding	NN
149	150	.	.	.

152	155	The	the	DT
156	162	active	active	JJ
163	170	nuclear	nuclear	JJ
171	175	form	form	NN
176	178	of	of	IN
179	182	the	the	DT
183	191	NF-kappa	NF-kappa	NNP
192	193	B	B	NNP
194	207	transcription	transcription	NN
208	214	factor	factor	NN
215	222	complex	complex	NN
223	225	is	be	VBZ
226	234	composed	compose	VBN
235	237	of	of	IN
238	241	two	two	CD
242	245	DNA	dna	NN
246	253	binding	binding	NN
254	262	subunits	subunit	NNS
262	263	,	,	,
264	272	NF-kappa	NF-kappa	NNP
273	274	B	B	NNP
275	278	p65	p65	NN
279	282	and	and	CC
283	291	NF-kappa	NF-kappa	NNP
292	293	B	B	NNP
294	297	p50	p50	NN
297	298	,	,	,
299	303	both	both	DT
304	306	of	of	IN
307	312	which	which	WDT
313	318	share	share	VBP
319	328	extensive	extensive	JJ
329	339	N-terminal	n-terminal	JJ
340	348	sequence	sequence	NN
349	357	homology	homology	NN
358	362	with	with	IN
363	366	the	the	DT
367	372	v-rel	v-rel	NN
373	381	oncogene	oncogene	NN
382	389	product	product	NN
389	390	.	.	.

391	394	The	the	DT
395	403	NF-kappa	NF-kappa	NNP
404	405	B	B	NNP
406	409	p65	p65	NN
410	417	subunit	subunit	NN
418	426	provides	provide	VBZ
427	430	the	the	DT
431	446	transactivation	transactivation	NN
447	455	activity	activity	NN
456	458	in	in	IN
459	463	this	this	DT
464	471	complex	complex	NN
472	475	and	and	CC
476	482	serves	serve	VBZ
483	485	as	as	IN
486	488	an	an	DT
489	502	intracellular	intracellular	JJ
503	511	receptor	receptor	NN
512	515	for	for	IN
516	517	a	a	DT
518	529	cytoplasmic	cytoplasmic	JJ
530	539	inhibitor	inhibitor	NN
540	542	of	of	IN
543	551	NF-kappa	NF-kappa	NNP
552	553	B	B	NNP
553	554	,	,	,
555	561	termed	term	VBN
562	563	I	i	NN
564	569	kappa	kappa	NN
570	572	B.	B.	NNP
573	575	In	in	IN
576	584	contrast	contrast	NN
584	585	,	,	,
586	594	NF-kappa	NF-kappa	NNP
595	596	B	B	NNP
597	600	p50	p50	NN
601	606	alone	alone	RB
607	612	fails	fail	VBZ
613	615	to	to	TO
616	625	stimulate	stimulate	VB
626	631	kappa	kappa	NN
632	642	B-directed	b-directed	JJ
643	656	transcription	transcription	NN
656	657	,	,	,
658	661	and	and	CC
662	667	based	base	VBN
668	670	on	on	IN
671	676	prior	prior	JJ
677	679	in	in	FW
680	685	vitro	vitro	FW
686	693	studies	study	NNS
693	694	,	,	,
695	697	is	be	VBZ
698	701	not	not	RB
702	710	directly	directly	RB
711	720	regulated	regulate	VBN
721	723	by	by	IN
724	725	I	i	NN
726	731	kappa	kappa	NN
732	734	B.	B.	NNP
735	737	To	to	TO
738	749	investigate	investigate	VB
750	753	the	the	DT
754	763	molecular	molecular	JJ
764	769	basis	basis	NN
770	773	for	for	IN
774	777	the	the	DT
778	786	critical	critical	JJ
787	797	regulatory	regulatory	JJ
798	809	interaction	interaction	NN
810	817	between	between	IN
818	826	NF-kappa	NF-kappa	NNP
827	828	B	B	NNP
829	832	and	and	CC
833	834	I	i	NN
835	840	kappa	kappa	NN
841	848	B/MAD-3	b/mad-3	NN
848	849	,	,	,
850	851	a	a	DT
852	858	series	series	NN
859	861	of	of	IN
862	867	human	human	JJ
868	876	NF-kappa	NF-kappa	NNP
877	878	B	B	NNP
879	882	p65	p65	NN
883	890	mutants	mutant	NNS
891	894	was	be	VBD
895	905	identified	identify	VBN
906	910	that	that	WDT
911	923	functionally	functionally	RB
924	934	segregated	segregate	VBD
935	938	DNA	dna	NN
939	946	binding	binding	NN
946	947	,	,	,
948	949	I	i	NN
950	955	kappa	kappa	NN
956	966	B-mediated	b-mediated	JJ
967	977	inhibition	inhibition	NN
977	978	,	,	,
979	982	and	and	CC
983	984	I	i	NN
985	990	kappa	kappa	NN
991	1000	B-induced	b-induced	JJ
1001	1008	nuclear	nuclear	JJ
1009	1018	exclusion	exclusion	NN
1019	1021	of	of	IN
1022	1026	this	this	DT
1027	1040	transcription	transcription	NN
1041	1047	factor	factor	NN
1047	1048	.	.	.

1049	1056	Results	result	NNS
1057	1061	from	from	IN
1062	1064	in	in	FW
1065	1069	vivo	vivo	FW
1070	1080	expression	expression	NN
1081	1088	studies	study	NNS
1089	1098	performed	perform	VBN
1099	1103	with	with	IN
1104	1109	these	these	DT
1110	1118	NF-kappa	NF-kappa	NNP
1119	1120	B	B	NNP
1121	1124	p65	p65	NN
1125	1132	mutants	mutant	NNS
1133	1141	revealed	reveal	VBD
1142	1145	the	the	DT
1146	1155	following	following	NN
1155	1156	:	:	:
1157	1158	1	1	LS
1158	1159	)	)	)
1160	1161	I	i	NN
1162	1167	kappa	kappa	NN
1168	1175	B/MAD-3	b/mad-3	NN
1176	1186	completely	completely	RB
1187	1195	inhibits	inhibit	VBZ
1196	1204	NF-kappa	NF-kappa	NNP
1205	1206	B	B	NNP
1207	1220	p65-dependent	p65-dependent	JJ
1221	1236	transcriptional	transcriptional	JJ
1237	1247	activation	activation	NN
1248	1256	mediated	mediate	VBN
1257	1264	through	through	IN
1265	1268	the	the	DT
1269	1274	human	human	JJ
1275	1291	immunodeficiency	immunodeficiency	NN
1292	1297	virus	virus	NN
1298	1302	type	type	NN
1303	1304	1	1	CD
1305	1310	kappa	kappa	NN
1311	1312	B	B	NNP
1313	1321	enhancer	enhancer	NN
1322	1324	in	in	IN
1325	1330	human	human	JJ
1331	1332	T	t	NN
1333	1344	lymphocytes	lymphocyte	NNS
1344	1345	,	,	,
1346	1347	2	2	LS
1347	1348	)	)	)
1349	1352	the	the	DT
1353	1360	binding	binding	NN
1361	1363	of	of	IN
1364	1365	I	i	NN
1366	1371	kappa	kappa	NN
1372	1379	B/MAD-3	b/mad-3	NN
1380	1382	to	to	TO
1383	1391	NF-kappa	NF-kappa	NNP
1392	1393	B	B	NNP
1394	1397	p65	p65	NN
1398	1400	is	be	VBZ
1401	1411	sufficient	sufficient	JJ
1412	1414	to	to	TO
1415	1423	retarget	retarget	VB
1424	1432	NF-kappa	NF-kappa	NNP
1433	1434	B	B	NNP
1435	1438	p65	p65	NN
1439	1443	from	from	IN
1444	1447	the	the	DT
1448	1455	nucleus	nucleus	NN
1456	1458	to	to	TO
1459	1462	the	the	DT
1463	1472	cytoplasm	cytoplasm	NN
1472	1473	,	,	,
1474	1475	3	3	LS
1475	1476	)	)	)
1477	1486	selective	selective	JJ
1487	1495	deletion	deletion	NN
1496	1498	of	of	IN
1499	1502	the	the	DT
1503	1513	functional	functional	JJ
1514	1521	nuclear	nuclear	JJ
1522	1534	localization	localization	NN
1535	1541	signal	signal	NN
1542	1549	present	present	JJ
1550	1552	in	in	IN
1553	1556	the	the	DT
1557	1560	Rel	Rel	NNP
1561	1569	homology	homology	NN
1570	1576	domain	domain	NN
1577	1579	of	of	IN
1580	1588	NF-kappa	NF-kappa	NNP
1589	1590	B	B	NNP
1591	1594	p65	p65	NN
1595	1603	disrupts	disrupt	VBZ
1604	1607	its	its	PRP$
1608	1615	ability	ability	NN
1616	1618	to	to	TO
1619	1625	engage	engage	VB
1626	1627	I	i	NN
1628	1633	kappa	kappa	NN
1634	1641	B/MAD-3	b/mad-3	NN
1641	1642	,	,	,
1643	1646	and	and	CC
1647	1648	4	4	LS
1648	1649	)	)	)
1650	1653	the	the	DT
1654	1660	unique	unique	JJ
1661	1671	C-terminus	C-terminus	NNP
1672	1674	of	of	IN
1675	1683	NF-kappa	NF-kappa	NNP
1684	1685	B	B	NNP
1686	1689	p65	p65	NN
1690	1700	attenuates	attenuate	VBZ
1701	1704	its	its	PRP$
1705	1708	own	own	JJ
1709	1716	nuclear	nuclear	JJ
1717	1729	localization	localization	NN
1730	1733	and	and	CC
1734	1742	contains	contain	VBZ
1743	1752	sequences	sequence	NNS
1753	1757	that	that	WDT
1758	1761	are	be	VBP
1762	1770	required	require	VBN
1771	1774	for	for	IN
1775	1776	I	i	NN
1777	1782	kappa	kappa	NN
1783	1793	B-mediated	b-mediated	JJ
1794	1804	inhibition	inhibition	NN
1805	1807	of	of	IN
1808	1816	NF-kappa	NF-kappa	NNP
1817	1818	B	B	NNP
1819	1822	p65	p65	NN
1823	1826	DNA	dna	NN
1827	1834	binding	binding	NN
1835	1843	activity	activity	NN
1843	1844	.	.	.

1845	1853	Together	together	RB
1853	1854	,	,	,
1855	1860	these	these	DT
1861	1869	findings	finding	NNS
1870	1877	suggest	suggest	VBP
1878	1882	that	that	IN
1883	1886	the	the	DT
1887	1894	nuclear	nuclear	JJ
1895	1907	localization	localization	NN
1908	1914	signal	signal	NN
1915	1918	and	and	CC
1919	1934	transactivation	transactivation	NN
1935	1941	domain	domain	NN
1942	1944	of	of	IN
1945	1953	NF-kappa	NF-kappa	NNP
1954	1955	B	B	NNP
1956	1959	p65	p65	NN
1960	1970	constitute	constitute	VBP
1971	1972	a	a	DT
1973	1982	bipartite	bipartite	JJ
1983	1989	system	system	NN
1990	1994	that	that	WDT
1995	1997	is	be	VBZ
1998	2008	critically	critically	RB
2009	2017	involved	involve	VBN
2018	2020	in	in	IN
2021	2024	the	the	DT
2025	2035	inhibitory	inhibitory	JJ
2036	2044	function	function	NN
2045	2047	of	of	IN
2048	2049	I	i	NN
2050	2055	kappa	kappa	NN
2056	2063	B/MAD-3	b/mad-3	NN
2063	2064	.	.	.

2065	2077	Unexpectedly	unexpectedly	RB
2077	2078	,	,	,
2079	2082	our	our	PRP$
2083	2085	in	in	FW
2086	2090	vivo	vivo	FW
2091	2098	studies	study	NNS
2099	2103	also	also	RB
2104	2115	demonstrate	demonstrate	VBP
2116	2120	that	that	IN
2121	2122	I	i	NN
2123	2128	kappa	kappa	NN
2129	2136	B/MAD-3	b/mad-3	NN
2137	2142	binds	bind	VBZ
2143	2151	directly	directly	RB
2152	2154	to	to	TO
2155	2163	NF-kappa	NF-kappa	NNP
2164	2165	B	B	NNP
2166	2169	p50	p50	NN
2169	2170	.	.	.

2171	2175	This	this	DT
2176	2187	interaction	interaction	NN
2188	2190	is	be	VBZ
2191	2201	functional	functional	JJ
2202	2204	as	as	IN
2205	2207	it	it	PRP
2208	2213	leads	lead	VBZ
2214	2216	to	to	TO
2217	2228	retargeting	retargeting	NN
2229	2231	of	of	IN
2232	2240	NF-kappa	NF-kappa	NNP
2241	2242	B	B	NNP
2243	2246	p50	p50	NN
2247	2251	from	from	IN
2252	2255	the	the	DT
2256	2263	nucleus	nucleus	NN
2264	2266	to	to	TO
2267	2270	the	the	DT
2271	2280	cytoplasm	cytoplasm	NN
2280	2281	.	.	.

2282	2289	However	however	RB
2289	2290	,	,	,
2291	2293	no	no	DT
2294	2298	loss	loss	NN
2299	2301	of	of	IN
2302	2305	DNA	DNA	NNP
2306	2313	binding	binding	NN
2314	2322	activity	activity	NN
2323	2325	is	be	VBZ
2326	2334	observed	observe	VBN
2334	2335	,	,	,
2336	2346	presumably	presumably	RB
2347	2357	reflecting	reflect	VBG
2358	2361	the	the	DT
2362	2368	unique	unique	JJ
2369	2379	C-terminal	c-terminal	JJ
2380	2386	domain	domain	NN
2387	2391	that	that	WDT
2392	2394	is	be	VBZ
2395	2403	distinct	distinct	JJ
2404	2408	from	from	IN
2409	2413	that	that	DT
2414	2421	present	present	JJ
2422	2424	in	in	IN
2425	2433	NF-kappa	NF-kappa	NNP
2434	2435	B	B	NNP
2436	2439	p65	p65	NN
2439	2440	.	.	.